Jubilant Pharmova Limited , a prominent player in the pharmaceutical sector, has announced that its wholly-owned subsidiary, Jubilant Biosys Limited, has received a significant GST demand order. The order, issued by the Deputy Commissioner of Commercial Taxes in Mysuru, Karnataka, amounts to Rs 13.77 crore for the Financial Year 2021-2022.

Details of the GST Demand

The adjudication order breaks down the total demand as follows:

The dispute primarily revolves around issues related to the availment and reversal of Input Tax Credit (ITC) during the fiscal year 2021-2022. The order alleges excess or irregular availment of Input Tax Credit and denies the benefit of GST reduction on credit notes issued by the company.

Company's Response

Jubilant Pharmova has stated that it plans to file a detailed appeal contesting the GST demand and penalty before the GST Appellate Authority. The company maintains that the Adjudication Order is legally incorrect and has been passed without properly examining the issues at hand. As a result, Jubilant Pharmova believes it has a strong case in its favor.

Financial Impact

Despite the substantial amount involved in the GST demand, Jubilant Pharmova expects no financial or operational impact from this development. This confidence likely stems from the company's belief in the merits of its case.

Conclusion

While the GST demand of Rs 13.77 crore is significant, Jubilant Pharmova's confident stance and plans to appeal suggest that the company is prepared to address this challenge. Investors and stakeholders will likely be watching closely as the appeal process unfolds, but for now, the company maintains that there will be no material impact on its operations or finances.

As the situation develops, it will be crucial to monitor any updates on the appeal process and any potential implications for Jubilant Pharmova's financial statements in the coming quarters.

Jubilant Pharmova Limited , a global pharmaceutical company, has announced the completion of a United States Food and Drug Administration (USFDA) audit at its contract manufacturing facility in Montreal, Canada. The audit, which concluded on November 3, 2025, resulted in 9 observations from the regulatory authority.

Audit Details

The USFDA audit was conducted at the facility operated by Jubilant HollisterStier General Partnership (JHSGP), which is jointly owned by subsidiaries of Jubilant Pharma Limited, a wholly-owned subsidiary of Jubilant Pharmova Limited. The company has stated that it will submit an action plan to address the observations made during the audit.

Key Points

Company Overview

Jubilant Pharmova Limited, formerly known as Jubilant Life Sciences Limited, is a diverse pharmaceutical company with global operations. The company's portfolio includes:

• Radiopharmaceuticals
• Allergy Immunotherapy
• Contract Development and Manufacturing Organization (CDMO) for Sterile Injectables
• Contract Research and Development Manufacturing Organization (CRDMO)
• Generics
• Proprietary Novel Drugs

The company operates multiple manufacturing facilities catering to regulated markets worldwide, including the USA and Europe. With a workforce of approximately 5,500 employees across the globe, Jubilant Pharmova has established itself as a 'Partner of Choice' for leading pharmaceutical companies.

Implications

While the specific details of the USFDA observations have not been disclosed, such audits are crucial for pharmaceutical companies operating in regulated markets. The outcome of this audit and the company's response to the observations may have implications for Jubilant Pharmova's operations and regulatory compliance status.

Investors and stakeholders will likely be watching closely to see how the company addresses these observations and any potential impact on its contract manufacturing business in North America.

As the pharmaceutical industry continues to face stringent regulatory scrutiny, the ability to successfully navigate such audits and maintain compliance remains a critical factor for companies operating in this sector.